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Abstract
Expression of MYC is deregulated in a wide range of human cancers, and is often associated with aggressive disease and
poorly differentiated tumor cells. Identification of compounds with selectivity for cells overexpressing MYC would hence be
beneficial for the treatment of these tumors. For this purpose we used cell lines with conditional MYCN or c-MYC expression,
to screen a library of 80 conventional cytotoxic compounds for their ability to reduce tumor cell viability and/or growth in a
MYC dependent way. We found that 25% of the studied compounds induced apoptosis and/or inhibited proliferation in a
MYC-specific manner. The activities of the majority of these were enhanced both by c-MYC or MYCN over-expression.
Interestingly, these compounds were acting on distinct cellular targets, including microtubules (paclitaxel, podophyllotoxin,
vinblastine) and topoisomerases (10-hydroxycamptothecin, camptothecin, daunorubicin, doxorubicin, etoposide) as well as
DNA, RNA and protein synthesis and turnover (anisomycin, aphidicholin, gliotoxin, MG132, methotrexate, mitomycin C). Our
data indicate that MYC overexpression sensitizes cells to disruption of specific pathways and that in most cases c-MYC and
MYCN overexpression have similar effects on the responses to cytotoxic compounds. Treatment of the cells with
topoisomerase I inhibitors led to down-regulation of MYC protein levels, while doxorubicin and the small molecule MYRA-A
was found to disrupt MYC-Max interaction. We conclude that the MYC pathway is only targeted by a subset of conventional
cytotoxic drugs currently used in the clinic. Elucidating the mechanisms underlying their specificity towards MYC may be of
importance for optimizing treatment of tumors with MYC deregulation. Our data also underscores that MYC is an attractive
target for novel therapies and that cellular screenings of chemical libraries can be a powerful tool for identifying
compounds with a desired biological activity.
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Introduction
The MYC transcription factor is one of the most potent and
commonly deregulated oncoproteins in human cancers [1,2]. It is
a member of the basic helix-loop-helix/leucine zipper (bHLH-Zip)
family of transcriptional regulators, and requires heterodimeriza-
tion with the Max protein for DNA binding to promote its
biological functions [3,4]. In addition to its role in cell
transformation, MYC plays an important role in the regulation
of cellular functions such as cell cycle progression, cell growth,
apoptosis, proliferation, differentiation, angiogenesis and mainte-
nance of genetic stability [2,3,5]. Moreover, the dual role of the
MYC family members in regulation of the cell cycle and apoptosis
implicate them as therapeutic targets [6,7].
Deregulation of the MYC family members c-MYC, MYCN and
MYCL are implicated in the genesis of human cancers and is
frequently strongly correlated with poor prognosis [1,2]. In Burkitt
lymphoma (BL), c-MYC is translocated to one of the immuno-
globulin loci resulting in its constitutive expression [8]. In many
solid tumors, MYC is instead amplified or otherwise deregulated.
For example, amplification of MYCN is a hallmark of neuroblas-
toma (NB), and is also observed in other tumors including
medulloblastoma, rhabdomyosarcoma, glioma and lung cancer
(for review see [1,9]. Current treatment regimens for patients with
BL includes a battery of cytotoxic drugs such as alkylating agents,
microtubule-targeting agents, topoisomerase inhibitors and anti-
biotics together with the dihydrofolate reductase (DHFR) inhibitor
methotrexate [10–12]. Despite documented efficacy of current
treatment schemes for BL, these are often associated with
undesired and sometimes severe side-effects [10,12]. Treatment
schemes for NB patients consist of multimodal therapy, combining
surgery, radiotherapy and chemotherapy, complemented in some
cases with bone marrow transplantation, depending on disease
stage. Chemotherapeutic treatment mainly involves combinations
of alkylating agents, microtubule-targeting agents, topoisomerase
inhibitors, and antibiotics. MYCN-amplification is associated with
the most aggressive phenotype of neuroblastoma. The survival rate
for high-risk NB is approximately 30% despite advances in
treatment strategies. Typically neuroblastomas are initially sensi-
tive to cytotoxic agents, but drug resistance often develops in high-
risk disease. Current efforts are trying to avoid or overcome this
effect [13–16]. Thus, identification of novel non cross-resistant
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effects are needed. In the case of BL and MYCN-amplified NB,
drugs that specifically target cells with deregulated MYC may
provide such a treatment.
MYC overexpression has been shown to sensitize cells to
apoptosis in response to a variety of cellular stresses, including
death receptor ligation, hypoxia, DNA damage and cytotoxic
drugs. The pro-apoptotic role of MYC overexpression is mainly
exhibited when survival factors are limiting. Several apoptosis
signaling pathways such as the p14/ARF-p53 pathway are
activated by MYC overexpression. In addition, there is a pro-
apoptotic shift in the balance among the Bcl-2 family proteins
(reviewed in [17]). The pro-apoptotic function of overexpressed
MYC is often overcome during tumor development by various
additional lesions that block apoptosis. These anti-apoptotic
changes may also contribute to drug resistance [18]. Hence, the
role of MYC in drug responses is not clarified and there are
conflicting data regarding the effect of MYC overexpression on the
sensitivity to cytotoxic agents [19–29]. Identification of pathways
that MYC overexpressing cancer cells, but not normal cells,
depend upon for their survival is an attractive strategy for
understanding the best way of treating MYC-deregulated cancers.
Here we used a library of 80 cytotoxic compounds with defined
mechanisms of action in order to identify drugs, which are more
potent in cells that overexpress MYC compared to those with
normal levels. Using the human B-cell derived p493-6 and the
human NB-derived Tet21 N cell lines with conditional expression
of c-MYC and MYCN respectively, we show that a limited
number of agents, acting through distinct mechanisms, are more
effective in MYC overexpressing tumor cells.
Results
MYC overexpression enhances the effect of a limited set
of conventional cytotoxic drugs
To analyze the impact of deregulated MYC expression on the
effect of conventional cytotoxic drugs with known mechanisms of
action, we screened a library of 80 selected compounds used in the
clinic or for research purposes (Table S1). The amount of viable
cells after 48 h treatment using 1 mM of each drug was evaluated
in order to identify drugs, which resulted in fewer viable cells in
MYCN overexpressing Tet21 N cells or in c-MYC overexpressing
p493-6 cells as compared to cells in which MYC was turned off.
Using a difference of 30% as cut-off, 15 drugs scored positive in
both cell lines (Table 1). In addition, four drugs (actinomycin D,
cycloheximide, geldanamycin and 17-allylamino-geldanamycin)
scored positive only in the MYCN overexpressing cells whereas
aphidicolin was the single drug that was more effective only in the
c-MYC overexpressing cells. In summary, there was a large
overlap of positive hits between the two cellular systems used,
indicating that overexpression of either c-MYC or MYCN in
different cellular contexts results in similar response to treatment
with cytotoxic drugs.
Although the drugs showing potentiated effect by MYC
overexpression acted on different cellular targets, there was
enrichment for compounds belonging to certain drug classes.
Not surprisingly many drugs targeting cycling cells were
potentiated by MYC overexpression. All three microtubule-
targeting agents included in the library had a greater effect when
either c-MYC or MYCN was overexpressed. In addition, 5 out of
7 topoisomerase inhibitors were more than 30% more efficient
when either MYCN or c-MYC was overexpressed (Figure 1A, B,
Table 1, Table S1). The remaining two topoisomerase II
inhibitors, Ellipticine and ICRF-193, showed some potentiation
by MYC overexpression but failed to reach our cut-off (Table S1).
Furthermore, both proteasome inhibitors included were selected
by the screen, as were both protein synthesis inhibitors, although
the effect of cycloheximide was only potentiated in the MYCN
overexpressing cells. In addition, drugs inhibiting DNA and RNA
synthesis were selected. The effect of the two HSP90 inhibitors
analyzed were both potentiated in the MYCN overexpressing
Tet21 N cells only (Table 1 and Table S1). In conclusion, our data
suggested that MYC overexpression potentiated the effect of drugs
acting through several different, yet specific sets of mechanisms.
Effect of MYC overexpression on apoptosis induced by
the cytotoxic compounds
Since there seemed to be selectivity in the mechanisms of the
drugs whose effect could be potentiated by MYC overexpression,
we chose to further investigate the effect of four of the
topoisomerase inhibitors (Camptothecin [CPT], 10-hydroxy-
camptothecin [OH-CPT], Etoposide [ETO] and Doxorubicin
[DXR]) and the three microtubule-targeting agents (Paclitaxel
[TAX], Podophyllotoxin [POD] and Vinblastine [VBL]). The
histone deacetylase inhibitor Trichostatin-A (TSA) was also
included (Figure S1). To validate the MYC dependent effect we
determined the concentration dependence and IC50 values of
these drugs in the two screening assays used. All drugs displayed a
concentration dependent effect over the range of concentrations
examined (0.5 nM to 15 mM), except for TAX in p493-6 cells
(Table 2, Figure S2). The IC50 values for the four topoisomerase
inhibitors and the HDAC inhibitor TSA were all statistically
significantly lower in c-MYC/MYCN overexpressing cells
(p,0.05) compared to the low expressing counterparts. The three
microtubule-targeting drugs also showed lower IC50 values in the
MYC overexpressing cells but this did in most cases not reach a
statistical significance (Table 2). Thus, MYC overexpression
enhanced the response to the majority of the selected drugs over
a broad range of concentrations.
The crystal violet and WST-1 assays used in the screen measure
the combined effect of the drugs on cell growth inhibition and cell
death (Figure 1A, B). Since MYC promotes proliferation and
MYC overexpression can sensitize cell to apoptosis, the influence
of MYC expression on the outcome of these drugs could be due to
effects on either of these processes. To determine the effect of
MYC overexpression on the induction of apoptosis, we quantified
cells with subG1 DNA content in drug-treated p493-6 and
Tet21 N cells in the presence or absence of doxycycline (Figure 1C,
D). In p493-6 cells, TSA and the three microtubule-targeting
agents (TAX, POD VBL) induced significantly more apoptosis
when c-MYC was overexpressed. The three topoisomerase
inhibitors (10-OH-CPT, DXR and ETO) showed a similar
tendency but this failed to reach statistical significance. In the
Tet21 N cells on the other hand, even though all drugs induced
apoptosis to variable extent, only TSA induced significantly more
apoptosis in the MYCN overexpression setting. This indicated that
the difference seen in the crystal violet assay depending on MYCN
status (Figure 1B) at this drug concentration was due to effects on
proliferation, or alternatively due to modes of cell death not
involving DNA fragmentation.
The p53-deficient MYCN-amplified NB cell line SK-N-BE(2)
efficiently forms colonies when plated in soft agar. All drugs, with
the exception of ETO, completely inhibited anchorage indepen-
dent growth in soft agar of these cells at a concentration of 1 mM
(Figure 2). Increasing the ETO concentration to 10 mM also
resulted in complete inhibition of colony formation (data not
shown). This shows that the selected drugs could target MYCN-
amplified neuroblastoma, independently of p53 activation.
Cytotoxic Drugs Selective for MYC Overexpression
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expression levels
Experimental models have shown that some tumors can be
dependent on sustained expression of MYC, referred to as
oncogene addiction. Hence withdrawal of MYC can lead to
tumor regression associated with tumor cell death, senescence
and/or differentiation [30–32]. With this in mind we wanted to
understand if the enhanced efficacy of some of the compounds
observed in MYC overexpressing cells could be due to inhibition
of MYC function. We therefore monitored the effects of drug
treatment on c-MYC protein expression. Western blot analysis of
c-MYC revealed a decrease in the c-MYC protein levels after
treatment with the topoisomerase I inhibitors CPT and OH-CPT,
as well as with the HDAC inhibitor TSA and to a lesser extent
DXR, which can inhibit both topoisomerase I and II (Figure 3A,
C). In contrast, we could not observe any significant effect on c-
MYC protein levels after treatment with ETO or with any of the
microtubule-targeting agents. If anything, there was a slight
increase in protein levels (Figure 4A, B).
Since c-MYC is expressed from a Tet-responsive promoter in
the p493-6 cells the effect of the drugs on c-MYC expression levels
could be due to unspecific effect on the Tet-OFF-system. To rule
this out we analyzed whether any of the drugs affected the
luciferase signal in a cell line expressing the firefly luciferase gene
under the control of a Tet-responsive promoter (CHO AA8-Luc
Tet-OFF). Doxycyline-treatment led, as expected, to a robust
decrease in the luciferase activity (Figure S3). In contrast, we could
not detect any decrease in the luciferase signal after treatment with
1 mM of any of the cytotoxic drugs tested, verifying that they did
not mimic the effect of doxycycline in the Tet-OFF system (Figure
S3). In addition we treated the BL cell lines Raji and Daudi with
CPT and OH-CPT to analyze effects on MYC expression.
Treatment with 1 mM of each drug for 48 h resulted in a similar
decrease in c-MYC levels in these BL cell lines as in the p493-6
cells (Figure 4A and data not shown). Together these experiments
show that the observed down-regulation of c-MYC in the p493-6
was not due to unspecific effects on the Tet-OFF system but
worked through an alternative mechanism.
To validate that the decreased c-MYC levels after topoisomer-
ase I inhibition was not simply due to cell death we monitored
kinetics of c-MYC regulation and cell death induction after
treatment of p493-6 cells with OH-CPT. Upon treatment with
1 mM of the topoisomerase I inhibitor c-MYC down-regulation
was evident already within 6 h (Figure 4A), while apoptosis
induction was observed at low levels after 24 h and was fully
evident only after 48 h (Figure 4B). Furthermore, treatment with
Table 1. Drugs that selectively targets MYC overexpressing cells.
SUBSTANCE TARGET/EFFECT ASSAY*
Tet21 N (MYCN) p493-6 (c-MYC)
Potentiation by MYCN and c-MYC
Mitomycin C alkylating agent ++ +++
Methotrexate dihydrofolate reductase (DHFR) inhibitor (inhibition of DNA and RNA synthesis) ++ ++
Trichostatin-A histone deacetylase inhibitor ++ +++
Anisomycin protein synthesis inhibitor ++ ++
Staurosporine kinase inhibitor +++ ++
Gliotoxin inhibitor of 20 S-proteasome chymotrypsin activity ++ ++
MG-132 proteasome inhibitor +++ ++
Camptothecin topoisomerase I inhibitor +++ ++
10-Hydroxycamptothecin topoisomerase I inhibitor +++ ++
Daunorubicin DNA intercalator. Inhibits topoisomerase I and II. RNA and DNA synthesis inhibitor.
Induces DNA single-strand breaks
+++ ++
Doxorubicin DNA intercalator Inhibits topoisomerase I and II. RNA and DNA synthesis inhibitor.
Induces DNA single-strand breaks
+++ ++
Etoposide topoisomerase II poison ++ ++
Podophyllotoxin tubulin polymerization inhibitor +++ ++
Paclitaxel microtubule stabilizer +++ ++
Vinblastine tubulin inhibitor +++ +++
Potentiation by MYCN
Actinomycin D RNA synthesis inhibitor +++ NE
Cycloheximide protein synthesis inhibitor ++ +
17-Allylamino-geldanamycin HSP-90 inhibitor +++ +
Geldanamycin HSP90 inhibitor +++ +
Potentiation by c-MYC
Aphidicolin DNA polymerase inhibitor (inhibition of DNA synthesis) + +++
*Decrease in number of viable cells expressed as % inhibition in MYC-ON cells compared to MYC-OFF cells, calculated as the difference between (optical density [OD] for
drug treated MYC-OFF cells)/(OD for DMSO treated MYC-OFF cells) and (OD for drug treated MYC-ON cells)/(OD for DMSO treated MYC-ON cells).
+, 10–35% inhibition; ++, 35–50% inhibition; +++,$50% inhibition; NE = No effect (#10% effect).
doi:10.1371/journal.pone.0027988.t001
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OH-CPT-induced apoptosis, could not rescue the c-MYC protein
levels (Figure 4C, D). In summary, our data indicate that
inhibition of topoisomerase I leads to a rapid reduction of c-
MYC levels that precedes the induction of apoptosis.
MYC/Max binding to DNA is disrupted by DXR
To further explore effects on MYC function, we performed
electrophoretic mobility shift assays (EMSAs) on cell extracts
treated with the different drugs to evaluate their effect on DNA
binding of the c-MYC/Max complex. At drug concentrations up
Figure 1. Effects on cell proliferation and cell death by selected MYC specific compounds. Quantification of the amount of viable cells
after 48 h of treatment with 1 mM of the indicated drugs, using WST-1 assay in p493-6 cells (A) or crystal violet staining in Tet21 N cells (B). Cells were
cultured in the presence of doxycycline (1 mg/ml) to turn off MYC expression or without doxycycline to allow MYC overexpression. Data are shown as
percent of control (DMSO) treated cells and represent the means of two independent experiments. Error bars indicate standard deviation.
Quantification of cell death by propidium iodide staining for sub-G1 DNA content of p493-6 cells (C) and Tet21 N cells (D), treated as in (A) and (B).
Data are shown as drug specific cell death induction (see Material and Methods) relative to control treated cells and represent the means of at least
three independent experiments. Error bars indicate standard deviation. * p,0.01, ** p,0.0001.
doi:10.1371/journal.pone.0027988.g001
Table 2. IC50 values in cells with low versus high MYC-expression status.
Tet21 N P493-6
MYCN on MYCN off c-MYC on c-MYC off
Drug IC50 (95% CI*) IC50 (95% CI) IC50 (95% CI) IC50 (95% CI)
Camptothecin 5.4 nM (3.5–7.3)
a 73 nM (48–97) 5.6 nM (2.4–8.7)
a 49 nM (28–70)
10-hydroxy-camptothecin 11 nM (7.2–15)
a 74 nM (40–110) 4.2 nM (1.0–7.4)
a 72 nM (31–110)
Etoposide 1.5 mM (0.85–2.2)
a .15 mM 0.22 mM (0.07–0.38)
a .15 mM
Doxorubicn 98 nM (69–130)
a 400 nM (220–580) 26 nM (5.8–45)
a 250 nM (150–340)
Podophyllotoxin 3.9 nM (2.8–5.0) 6.6 nM (4.1–9.0) 6.0 nM (3.0–9.0) 20 nM (3.5–37)
Paclitaxel 4.1 nM (2.0–6.2) 30 (,0.5–63) - -
Vinblastine 1.1 nM (0.6–1.6)
a 28 (3.8–52) ,0.5 nM 36 nM (,0.5–73)
Trichostatin-A 62 nM (50–75)
a 130 (88–1200) 17 nM (6.6–27)
a 140 nM (77–200)
*CI; Confidence interval.
aStatistically significant difference at the 95% confidence-level in the IC50 values between MYC on and MYC off conditions.
doi:10.1371/journal.pone.0027988.t002
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eight tested drugs had virtually no effect on the amount of c-
MYC/Max present on the E-box-containing CMD oligonucleo-
tide when incubated with p493-6 extracts (data not shown). In
contrast, DXR, completely disrupted DNA binding of complexes
containing c-MYC, Max or Mnt already at 10 mM, while USF
binding was apparently not affected (Figure 5A).
To further corroborate this finding, we also performed EMSAs
on extracts from cells that had been treated with DXR in culture,
as well as on extracts from cells treated with MYC Pathway
Response Agent-A (MYRA-A), a MYC pathway specific apoptosis
inducer that we previously showed to disrupt binding of MYC/
Max to DNA [33,34]. c-MYC/Max DNA binding was abrogated
in treated p493-6 cells at the lowest tested concentrations of the
drugs (2.5 mM and 5 mM respectively, Figure 5B). Similar results
were seen for MYCN/Max binding in DXR and MYRA-A
treated SK-N-BE(2) cells (Figure 5C). In summary, our data show
that DXR and MYRA-A can interfere with the DNA binding of c-
MYC/Max as well as MYCN/Max, and thus likely influences the
transcriptional activity of these complexes.
Discussion
MYC oncoproteins are aberrantly expressed in a wide variety of
human cancers, in most cases as a result from mutations at one or
multiple levels of the MYC pathway, making them attractive
targets for cancer therapy [1,9]. Several studies of tumor
formation in in vitro and in vivo systems with conditional MYC
expression have demonstrated that MYC induction promotes
tumor formation while its down-regulation causes tumor cell
growth arrest, enhanced apoptosis, senescence, tumor regression
and/or differentiation (for review see [35]). Animal studies have
shown that even a transient MYC downregulation appears to be
sufficient for diminishing tumor tissue and that the tumor may
actually regress upon MYC reactivation [30,31,36,37]. Further-
more, it was recently demonstrated that systemic inhibition of
endogenous MYC activity in mice caused regression of Ras-
Figure 2. Inhibition of anchorage independent growth of
neuroblastoma cells by selected MYC-specific compounds. SK-
N-BE(2) cells were seeded in soft agar and treated with 1 mM of the
eight reference compounds indicated. For each compound, the
colonies were counted and representative plates from two independent
experiments performed in duplicates are presented. DMSO treated cells
were used as control.
doi:10.1371/journal.pone.0027988.g002
Figure 3. Effects of drug treatment on c-MYC protein levels. (A) Western blot analysis of c-MYC expression in p493-6 cells treated for 48 h
with indicated concentrations of topoisomerase inhibitors (A), microtubule-targeting agents (B) or the HDAC-inhibitor trichostatin-A (C). Membranes
were probed with antibodies recognizing c-Myc and Actin was used as a loading control.
doi:10.1371/journal.pone.0027988.g003
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were well tolerated and completely reversible [32]. Thus,
interfering with the MYC pathway would potentially enable
elimination of malignant cells with low side effects for normal cells.
Alternatively, inhibition of pathways that MYC overexpressing
cells depend on for their survival could be exploited for targeting
these tumors.
Here, we have explored how substances with already charac-
terized cellular targets affect the MYC pathway and demonstrated
that the effects of only a subset of drugs, acting on selected cellular
targets, were enhanced by MYC overexpression. Contradictory
results regarding the correlation between MYC expression levels
and cellular sensitivity to chemotherapeutic drugs exist in the
literature. Reports showing that c-MYC overexpression confers
drug resistance [19,20,28] are challenged by others, including
studies from our group, demonstrating MYC-mediated sensitiza-
tion to a number of chemotherapeutic drugs [21,24–27]. This may
be due to diverse effects elicited by various drugs or by different
cellular contexts. We show in this study that the cytotoxic effects of
only a subset of the drugs in our screen were potentiated by MYC
overexpression, indicating that overexpression of MYC in cancer
cells does not lead to a general sensitization to cytotoxic drugs.
Instead our results suggest that MYC overexpression makes cells
vulnerable to targeting of specific biological processes. Particularly,
drugs targeting microtubules and topoisomerases were identified.
All three microtubule-targeting agents included in the screen
induced significantly more apoptosis in MYC overexpressing cells.
These agents act by disrupting spindle microtubule dynamics
during the mitotic phase of the cell cycle, leading to activation of
the spindle assembly checkpoint and mitotic arrest followed by cell
death [38]. Our data is in line with the observations by others that
Figure 4. c-MYC down-regulation upon topoisomerase I
inhibition precedes cell death induction. (A) Western blot of c-
MYC expression in p493-6 and Raji cells after 48 h treatment with 1 mM
of the indicated drugs. (B) Western blot analysis of c-MYC expression in
p493-6 cells before and after treatment for indicated times with 1 mMo f
10-OH-Camptothecin. (C) Cell death induction as measured by
propidium iodide staining and quantification of cells with subG1 DNA
content after treatment for indicated times with 1 mM of 10-OH-
Camptothecin. Data are shown as specific cell death induction relative
to control (DMSO) treated cells and represent the means of three
independent experiments. Error bars indicate standard deviation. (D)
Western blot analysis c-MYC expression in p493-6 treated for 48 h with
topoisomerase inhibitors in the presence or absence of the pan-caspase
inhibitor zVAD-fmk. (E) Cell death induction as measured by propidium
iodide staining and quantification of cells with subG1 DNA content of
cells treated with topoisomerase inhibitors in the presence or absence
of the pan-caspase inhibitor zVAD-fmk for 48 h. Data are shown as
specific cell death induction relative to control (DMSO) treated cells and
represent means from three independent experiments. Error bars
indicate standard deviations. * p,0.01.
doi:10.1371/journal.pone.0027988.g004
Figure 5. Doxorubicin inhibits MYC/Max DNA binding. Electro-
mobility shift assay showing binding of MYC network proteins in
extracts from p493-6 cell treated in vitro with DXR (A), or extracts from
p493-6 cells (B) or SK-N-BE(2) cells (C) treated in culture for 48 h with
DXR or MYRA-A. The Mnt/Max, USF, c-MYC/Max, and MYCN/Max DNA–
protein complexes were identified by antibody super shifts and are
indicated to the left.
doi:10.1371/journal.pone.0027988.g005
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[39–41] suggesting that MYC overexpressing cells are particularly
sensitive to disruption of these mitotic processes.
It has been suggested that the response to treatment is
dependent on which member of the MYC family that is
deregulated [42]. However, we observed to a large extent, similar
effects on cytotoxicity in cells with either deregulated c-MYC or
MYCN, indicating similar biological effects on the cells. This is in
agreement with recent demonstrations that high MYC-pathway
activity is associated with poor outcome of the disease in
neuroblastoma patients, irrespective of whether it was caused by
MYCN-amplification, by increased c-MYC level or by any other
cause [43,44].
We observed that the topoisomerase I inhibitors, as well as the
histone deacetylase inhibitor TSA, led to down-regulation of MYC
protein levels. Decreased MYC levels were also recently reported
after treatment with the topoisomerase I inhibitor Sn38 [45]. The
mechanism behind this down-regulation is currently unresolved.
In contrast we did not observe any down-regulation of MYC levels
by microtubule-targeting agents, and the relationship between
MYC expression and the cytotoxic effect of these agents appears to
be largely context dependent [23,26–28,46,47].
Doxorubicin was found to be unique among the studied drugs
since it could disrupt the binding of the MYC/Max complex to
DNA. We have previously shown a similar effect by the small
molecule MYRA-A [33]. Interestingly, the structure of MYRA-A
shares some similarity with that of DXR (Figure S1), suggesting
that they may act in an analogous way. DNA binding properties of
MYRA-A has indeed been suggested by others [48]. Similar to
what was previously shown for MYRA-A [33], DXR also
interfered with binding of Mnt/Max complexes to DNA, while
binding of USF remained unaltered. Hence not all DNA binding
proteins were affected. Even though USF binds to the same E-box
sequences as MYC/Max this could indicate different modes of
DNA-binding for the different factors. Detailed structural studies
would be required to understand how DXR and MYRA-A affect
the binding of these proteins to DNA.
In conclusion, overexpression of MYC renders tumor cells
particularly sensitive to targeting of certain mechanisms and
pathways, including topoisomerases and the mitotic control
machinery as shown in this study. Discovery of novel substances
is essential for development of future cancer therapies. It is also
important to analyze how the conventional cytotoxic drugs used in
the clinic today act in different cellular contexts. Comparison
between cells with normal and overexpressed MYC will help to
enhance our understanding of how to best use and combine
conventional drugs in cancer treatment. This information will
hopefully also be useful when developing novel cancer therapies.
Materials and Methods
Cell culture and drug treatments
The human NB SH-EP cell line with conditional MYCN
expression (Tet- 21 N, Tet-OFF system [49] was cultured in
RPMI 1640 medium supplemented with 10% FBS, 1% glutamine,
1% penicillin/streptomycin, G418 (200 mg/ml), and hygromycin
(100 mg/ml). The human B-cell line p493-6 with tetracycline
regulated (Tet-OFF) c-MYC expression [50] and the BL cell lines
Raji and Daudi was cultured in RPMI 1640 medium supple-
mented with 10% FBS, 1% glutamine, and 1% penicillin/
streptomycin. MYCN and c-MYC expression was regulated by
addition of doxycycline (l mg/ml, Sigma) for 20 h before drug
treatment. Human NB SK-N-BE(2) cells with amplified MYCN
were a gift from Per Kogner (Karolinska Institutet, Sweden) and
were grown in EMEM:F12-Ham medium (1:1, v/v) supplemented
with 10% FBS, 1% glutamine, 1% non-essential amino acids, and
1% penicillin/streptomycin. The Chinese hamster ovary derived
CHO AA8-Luc Tet-OFF cell line (Clontech), was maintained in
EMEM supplemented with 10% Tet-system approved FBS, 1% L-
glutamine, and 1% penicillin/streptomycin.
Reagents
The chemical library provided by Actar AB (Stockholm,
Sweden), consisted of 80 cytotoxic reference compounds with
known cellular targets (Table S1). Propidium Iodide and RNase A
were from Sigma and zVAD-fmk was from AG Scientific Inc. (San
Diego, CA). MYRA-A was kindly provided by NCI (Bethesda
MD).
Cell viability assays
To quantify the amount of living cells the WST-1 Cell
Proliferation reagent (Roche Diagnostics) was used for the non-
adherent p493-6 cells, according to the manufacturer’s instruc-
tions, while adherent Tet21 N cells were stained with crystal violet
(Sigma) as previously described [33].
IC50 determination
Tet-21 N and p493-6 cell were treated with drugs in a
concentration ranging from 0.5 nm to 15 mM for 48 h in the
presence or absence of doxycycline, after which the amount of
viable cells were quantified. For calculation of IC50 values with
95% confidence intervals Four Parameter Logistic best-fit
concentration-response curves were generated using XLfit add-in
for Excel (IDBS). Statistical significance for the differences in IC50
values was determined based on the 95% confidence intervals.
Flow cytometry analysis
Drug-induced apoptosis was scored by quantifying the subG1
fraction. Cells were fixed with 70% ice-cold methanol and stored
at +4uC over night or 220uC for longer times. Cells were stained
with propidium iodide solution (5 mg/ml propidium iodide and
25 mg/ml RNase A in PBS) for 30 min at 37uC, and analyzed in a
FACScan flow cytometer (Becton Dickinson). Apoptotic cells were
identified within the PI-stained population by virtue of exhibiting
an apparent sub diploid DNA content. Drug specific cell death was
defined as the percentage of apoptosis induced when adjusted for
background cell death level in control treated cells and calculated
as [(% apoptosis in drug treated cells)-(% apoptosis in control
treated cells)]/[100%-(% apoptosis in control treated cells)]*100%.
Luciferase Assay. Luciferase activity was measured using the
Dual-Luciferase Reporter Assay (Promega) according to the
instructions from the manufacturer. Protein concentrations of
the extracts used were determined using the Bradford method
(Bio-Rad Protein Assay, Bio-Rad). Luciferase signals were
normalized to the protein concentration.
Immunobotting
Whole-cell extracts were prepared using F-buffer and Western
blot analysis was performed as previously described [25].
Membranes were probed with mouse monoclonal anti-c-MYC
antibody (9E10, Santa Cruz Biothecnology Inc). Equal loading of
proteins was confirmed by re-probing the membranes with
antibodies specific for Actin (Sigma). HRP-conjugated anti-mouse
antibody (Amersham Biosciences) served as secondary reagent.
Blots were developed by enhanced chemiluminescence (ECL,
Amersham).
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To assess the drug effect on DNA binding of the MYC/Max
complex, EMSA was performed essentially as previously described
[51], using protein extracts from cells treated either in culture
(48 h incubation) or protein extracts treated in vitro with drug.
Briefly, 15 mg of protein from SK-N-BE(2) or p493-6 cells was
incubated for 30 min with sonicated salmon sperm DNA,
antibodies to identify relevant bands by super shift, and drugs
for the in vitro experiments at 25uC. This initial incubation was
followed by 30 min incubation with [c32P]ATP end-labeled
CMD probe at 25uC. The DNA-protein complexes were then
separated on 5.5% polyacrylamide gels in 25 mM Tris base,
20 mM boric acid, and 0.5 mM EDTA at 4uC, dried and
visualized on a phosphoimager. Specific bands were identified by
using the following antibodies for super shifts: M132 (Mnt), X
(USF), N262 (c-MYC), NCMII (MYCN) and C-17 (Max); all from
Santa Cruz Biotechnology, Inc.
Soft agar experiments
Single-cell suspension of SK-N-BE(2) cells in 0.4% SeaPlaque
agarose (Cambrex BioScience-Rockland, East Rutherford, NJ) was
seeded onto a 0.6% agarose base. After one hour, medium
containing the selected reference compounds was added to the top
of the gel and cultures were then incubated for 4 days. Medium
was thereafter changed every 3–4 days. Following incubation for
approximately 2 weeks, living cells and colonies were counted and
visualized by the addition of 100 mg/ml MTT reagent (Calbio-
chem). Two independent experiments were performed in
duplicates and the number of colonies formed in drug treated
cells was compared to the control (DMSO).
Supporting Information
Figure S1 Structures of the compounds used in the
study. Structures for the eight cytotoxic drugs selected for further
characterization of their effect on the MYC-pathway as well as the
structure of MYRA-A.
(TIF)
Figure S2 Concentration response curves for IC50
calculations. (A) Concentration-response curves for p493-6
cells treated with the indicated drugs in the presence (c-MYC
OFF) or absence (c-MYC ON) of doxycycline for 48 h. The
amount of viable cells was quantified using the WST1 reagent and
the percentage of viable cells relative to control (DMSO) treated
cells are depicted. (B) Concentration-response curves for Tet21 N
cells treated with the indicated drugs in the presence (MYCN
OFF) or absence (MYCN ON) of doxycycline for 48 h. The
amount of viable cells was quantified by crystal violet staining and
the percentage of viable cells relative to control (DMSO) treated
cells is depicted. Data represent 3–5 independent experiments.
(TIF)
Figure S3 Cytotoxic drugs do not mimic the effect of
doxycycline on the Tet-OFF promoter. CHO-AA8 Tet-
OFF-Luc cells were treated for 48 h with 1 mM of the indicated
cytotoxic drugs or with 1 mg/ml doxycycline. Luciferase activity
was assayed with the Dual-Luciferase Reporter Assay and the
luciferase signal was normalized to the protein concentration in
each extract analyzed. Data represent triplicates in each
experiment and error bars indicate standard deviation.
(TIF)
Table S1 Characteristics of the reference substances
used in the study. List of the 80 compounds in the chemical
library and their cellular targets. The effect on viability in cells
overexpressing MYCN or c-MYC relative to non-overexpressing
cells is shown for each compound.
(XLS)
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